Patients with NSCLC and tumor cell PD-L1 expression ≥1% who progressed after platinum-doublet chemotherapy were randomized 1:1:1 to receive pembrolizumab 2 mg/kg (n = 345), pembrolizumab 10 mg/kg (n = 346), or docetaxel 75 mg/m2 (n = 343) every 3 weeks; no crossover was allowed. This evidence concerns the gene CD274 and neoplasm.